7. Relapse Prevention And Effectiveness In Schizophrenia Of Risperidone Long-Acting Injectable (RLAI) Versus Quetiapine Or Aripiprazole. Poster presentado en la 161 Reunión de la American Psychiatric Association (APA), Washington, EE.UU. Del 3 al 8 de mayo de 2008. Proceedings/Abstract book, P.203, No-Nr4-094, 2008.
8. Gaebel W et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable versus quetiapine: randomised, long-term, open-label, clinical trials results (ConstaTRE). European Psychiatry 24 (suplemento 1).
Más información sobre Janssen-Cilag disponible en http://www.janssen-cilag.com.
BEERSE, Bélgica, June 3 /PRNewswire/ --
Sue Silk, responsable de CNS Communications EMEA, Tel: +44-1494-553-955; Johnson & Johnson Pharmaceutical Services E-mail: ssilk@its.jnj.com; Brigitte Byl, directora de comunicaciones farmacéuticas mundiales, Tel: +32-1460-7172; Johnson & Johnson Pharmaceutical Services, Email: bbyl@its.jnj.com
